Discover
DMRA
Damora Therapeutics, Inc.
21.08
2 x 15.17
2 x 26.75
bid
ask
+
0.52
2.53%
2 @ 04:01 PM
21.08 +0.00 (0.00%)
| Ytd | -8.39% | |
| 1y | 42.92% |
20.43
day range
21.86
4.95
52 week range
34.14
| Open | 20.53 | Prev Close | 20.56 | Low | 20.43 | High | 21.86 | Mkt Cap | 1.30B |
| Vol | 368.73K | Avg Vol | 531.94K | EPS | -0.26 | P/E | N/A | Forward P/E | -9.70 |
| Beta | 1.44 | Short Ratio | 10.91 | Inst. Own | 105.78% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 26.68 | 200-d Avg | 25.98 | 1yr Est | 46.89 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-11-05 | 2026-09 | -0.48 | N/A | N/A | N/A |
| 2026-08-11 | 2026-06 | -0.41 | -0.39 | 0.02 | 5.79% |
| 2026-05-12 | 2026-03 | -0.21 | -0.62 | -0.41 | -195.24% |
| 2026-03-18 | 2025-12 | -0.14 | -3.24 | -3.1 | -2216.35% |
| 2025-11-06 | 2025-09 | -0.1 | -2.36 | -2.26 | -2337.76% |
| 2025-08-05 | 2025-06 | 0 | -2.6 | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-09-29 | Wedbush | Upgrade | Outperform | Outperform |
| 2026-09-25 | Guggenheim | Upgrade | Buy | Buy |
| 2026-07-30 | Wedbush | Upgrade | Outperform | Outperform |
| 2026-07-27 | Jefferies | Upgrade | Buy | |
| 2026-07-21 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-06-12 | Wedbush | Upgrade | Outperform | Outperform |
Profile
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-02-08 | BRUNO JULIANNE | Director | 137.03K | Conversion of Exercise of derivative security |
| 2026-02-08 | FAIRMOUNT FUNDS MANAGEMENT LLC | Director and Beneficial Owner of more than 10% of a Class of Security | 0.00 | Conversion of Exercise of derivative security |
| 2026-01-01 | FIRMANI LORI | Chief Financial Officer | 931.00 | Sale |
| 2026-01-04 | HEWES LEMUEL BECKER | Officer | 264.63K | Stock Award(Grant) |
| 2026-09-24 | JARRETT A JENNIFER | Chief Executive Officer | 512.50K | Purchase |
| 2026-01-04 | SATTARZADEH SHERWIN | Chief Operating Officer | 190.38K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | Price (T.Rowe) Associates Inc | 48.74K | 1.03M | 0.08% |
| 2026-06-29 | Rothschild Investment LLC | 34.00 | 716.00 | 0.00% |
| 2026-06-29 | Harbour Investments, Inc. | 40.00 | 843.00 | 0.00% |
| 2026-09-29 | Gamma Investing LLC | 91.00 | 1.92K | 0.00% |
| 2026-09-29 | Farther Finance Advisors, Llc | 40.00 | 843.00 | 0.00% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-08-30 | Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 1.84M | 38.68M | 2.97% |
| 2026-08-30 | iShares Trust-iShares Russell 2000 ETF | 1.34M | 28.35M | 2.18% |
| 2026-07-30 | Fidelity Securities Fund-Fidelity Small Cap Growth Fund | 834.04K | 17.58M | 1.35% |
| 2026-08-30 | SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 754.69K | 15.91M | 1.22% |
| 2026-07-30 | Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 583.68K | 12.30M | 0.95% |
| 2026-08-30 | Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 540.25K | 11.39M | 0.88% |